More than 70% of juvenile localized scleroderma patients who took oral methotrexate were in clinical remission for a mean of 25 months, while 27.1% experienced remission while taking the drug, according to an Italian study in the Journal of the American Academy of Dermatology. Generally mild side effects were reported by 48.3% of respondents, but they didn't cause the patients to stop the medication.
Methotrexate shows promise for treating juvenile scleroderma
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Assistant Vice President - Dental Director||
|Vice President of Finance||
Urban Health Plan, Inc.